{
    "clinical_study": {
        "@rank": "19825", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Randomized 7 drug/2 placebo by group"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Randomized 7 drug/2 placebo by group"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Randomized 7 drug/2 placebo by group"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "Randomized 7 drug/2 placebo by group"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety, tolerability and pharmacokinetics of ABT-981 in patients with\n      osteoarthritis of the knee."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose\n      study. Thirty-six patients with osteoarthritis of the knee will be selected to participate.\n      Patients will be randomized to receive either ABT-981 or placebo. ABT-981 or placebo will be\n      administered as subcutaneous (under the skin) injections in  four dosing groups.  Subjects\n      will be administered subcutaneous injections of ABT-981 for up to 8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male or female, 40 to 70 years of age, inclusive.\n\n          -  History of symptomatic osteoarthritis (OA) of the knee joint for at least 3 months,\n             with typical Osteoarthritis (OA) symptoms\n\n          -  Radiographic Osteoarthritis (OA) of Kellgren-Lawrence (K-L) grade 1, 2 or 3\n\n          -  Patients assessment of Osteoarthritis (OA) pain intensity of the study joint is\n             between 40 and 80 on the 0 - 100 mm VAS scale\n\n          -  Other than Osteoarthritis (OA) of the study joint, patient should be in general good\n             health\n\n        Exclusion Criteria:\n\n          -  Radiographic OA of Kellgren-Lawrence grade 4 or chronic opioid user due to severe\n             knee OA\n\n          -  History of allergic reaction or significant sensitivity to any constituents of the\n             study drug and acetominophen or history of anaphylactic reaction to any agent\n\n          -  Significant trauma or surgery to the study joint within the last year or arthroscopy\n             within 6 months, or, scheduled for major surgery to the study joint\n\n          -  Diagnosis of rheumatoid arthritis, other autoimmune disorders or any arthritis other\n             than Osteoarthritis (OA) of the knee.\n\n          -  Any uncontrolled medical illness including unstable treatment or therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668511", 
            "org_study_id": "M12-756"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3", 
                    "Group 4"
                ], 
                "description": "Injection", 
                "intervention_name": "ABT-981", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2", 
                    "Group 3", 
                    "Group 4"
                ], 
                "description": "Placebo Injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Immunogenicity", 
            "Safety", 
            "Tolerability", 
            "Osteoarthritis", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "November 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "Site Reference ID/Investigator# 78613"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled Study in Patients With Osteoarthritis of the Knee to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of ABT-981", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Susanne  X. Wang, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Collect all adverse events at each visit", 
                "measure": "Number of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From date of first dose of ABT-981 until 70 days after the last dose of ABT-981"
            }, 
            {
                "description": "Blood pressure, heart rate and body temperature", 
                "measure": "Physical Exam including vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "From date of first dose of ABT-981 until 70 days after last dose of ABT-981"
            }, 
            {
                "description": "Hematology, Chemistry, and Urinalysis", 
                "measure": "Clinical Lab Testing", 
                "safety_issue": "Yes", 
                "time_frame": "From date of first dose of ABT-981 until 70 days after the last dose of ABT-981"
            }, 
            {
                "description": "ECGs done in triplicate", 
                "measure": "Change from Baseline in Electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "Prior to dose and 8 hours post dose on each day of dosing"
            }, 
            {
                "description": "Cmax", 
                "measure": "Maximum observed serum concentration (Cmax) of ABT-981", 
                "safety_issue": "No", 
                "time_frame": "Prior to first dose up to 70 days after the last dose of ABT-981"
            }, 
            {
                "description": "Time to Cmax", 
                "measure": "Time to Cmax (Tmax) of ABT-981", 
                "safety_issue": "No", 
                "time_frame": "Prior to first dose up to 70 days after the last dose of ABT-981"
            }, 
            {
                "description": "AUC", 
                "measure": "The area under the time curve (AUC) of ABT-981", 
                "safety_issue": "No", 
                "time_frame": "Prior to first dose up until 70 days after the last dose of ABT-981"
            }, 
            {
                "description": "The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-981", 
                "measure": "The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-981", 
                "safety_issue": "No", 
                "time_frame": "Prior to the last dose up to 70 days after the last dose of ABT-981"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668511"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measurement of ADA", 
            "measure": "Measurement of anti-drug anti-bodies  (ADA) of ABT-981", 
            "safety_issue": "Yes", 
            "time_frame": "Prior to each dose and up until 70 days after the last dose of ABT-981"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}